tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Heron Therapeutics sees FY24 Adjusted EBITDA ($22.0M)-$3.0M

Sees FY24 product revenues, net $138.0M-$158.0M; and adjusted operating expenses $108.0M-$116.0M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on HRTX:

Disclaimer & DisclosureReport an Issue

1